Yokote, Hiroaki
69  Ergebnisse:
Personensuche X
?
 
?
 
?
4

Post‐COVID‐19 vaccination Guillain–Barré syndrome with sens..:

Saso, Nanami ; Toru, Shuta ; Iwasaru, Keiichi..
Clinical and Experimental Neuroimmunology.  14 (2023)  3 - p. 142-145 , 2023
 
?
5

Long-term safety and effectiveness of eculizumab in patient..:

Nakashima, Ichiro ; Nakahara, Jin ; Yokote, Hiroaki...
Therapeutic Advances in Neurological Disorders.  16 (2023)  - p. , 2023
 
?
6

Eculizumab in AQP4+ neuromyelitis optica spectrum disorder:..:

Nakahara, Jin ; Nakashima, Ichiro ; Yokote, Hiroaki...
Journal of the Neurological Sciences.  455 (2023)  - p. 121844 , 2023
 
?
7

Multifocal motor neuropathy with conduction block that was ..:

Saito, Kazuyuki ; Yokote, Hiroaki ; Toru, Shuta
Clinical and Experimental Neuroimmunology.  14 (2023)  3 - p. 146-148 , 2023
 
?
8

High-efficacy therapy reduces subcortical grey matter volum..:

Yokote, Hiroaki ; Miyazaki, Yusei ; Toru, Shuta...
Multiple Sclerosis and Related Disorders.  67 (2022)  - p. 104077 , 2022
 
?
9

Theory of mind and its neuroanatomical correlates in people..:

Yokote, Hiroaki ; Okano, Kazumi ; Toru, Shuta
Multiple Sclerosis and Related Disorders.  55 (2021)  - p. 103156 , 2021
 
?
10

Author's response in reply to "Question about data: Importa..:

Yokote, Hiroaki
Journal of Neuroimmunology.  356 (2021)  - p. 577589 , 2021
 
?
14

A case of anti-AQP4 antibody–positive neuromyelitis optica ..:

Toru, Shuta ; Soejima, Itsuki ; Katayama, Yuki..
Multiple Sclerosis and Related Disorders.  46 (2020)  - p. 102557 , 2020
 
1-15